In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations. Rivaroxaban and apixaban are a selective, direct factor Xa inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhi, Li, Ying, He, Xueru, Fu, Yuhao, Li, Yajing, Zhou, Xin, Dong, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582335/
https://www.ncbi.nlm.nih.gov/pubmed/37860116
http://dx.doi.org/10.3389/fphar.2023.1263975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582335/
https://www.ncbi.nlm.nih.gov/pubmed/37860116
http://dx.doi.org/10.3389/fphar.2023.1263975

Ejemplares similares